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to have any significant benefit, failure of document- 
ing objective parameters of improvement such as 
lung volumes, failure to relate changes to clinically 
significant events, and lack of precise details of 
treatment protocols make interpretation and rec- 
ommendations extremely difficult. This reinforces the 
point made by Mr Ntoumenopoulos. 
In concluding, much of what is standard practice 
in medicine has never undergone a properly con- 
ducted randomized trial, and I am not suggesting 
that preoperative physiotherapy should be aban- 
doned because of a paucity of objective data as to its 
efficiency; but neither am I advocating that a high 
risk patient should be taken to surgery without a post 
operative management plan, in the often mistaken 
belief that preoperative physiotherapy will reduce the 
degree of risk. 
M. D. HAYHURST 
Department of Medicine and Respiratory Clinic 
Groote Schuur Hospital 
Observatory 7925 
Cape Town, South Africa 
29 June 1993 
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Dear Editor 
Intravenous antibiotic therapy in cystic fibrosis: in 
hospital or at home? 
We congratulate Drs Peckham and Knox (1) on 
their succinct review of the advantages of home 
intravenous antibiotic therapy in cystic fibrosis. 
Home i.v. therapy was introduced in Aberdeen in 
1974, partly because the ‘integration’ of the Health 
Services had made it difficult for administrative rea- 
sons for community-based nurses to give intramuscu- 
lar antibiotics in the home (as had previously been 
our practice), and partly because of the obvious 
benefits of this approach to treatment which had 
been reported from the U.S.A. (2). 
In 1990 we audited our home i.v. service and, in 
addition to the advantages identified by Peckham 
and Knox, we also identified a further, less easily 
quantifiable, benefit which we would like to highlight. 
Most parents reported that they had derived a great 
deal of satisfaction from this enhancement of their 
caring role; in participating actively in an important 
part of the medical care of their child, by ‘doing 
something which not even nurses are allowed to do’, 
they felt that the care they were giving was ‘complete’ 
and very rewarding. The psychological benefit there- 
fore extends beyond reducing the disruption of fam- 
ily life which accompanies hospital admission, to 
include some very positive feelings in favour of home 
treatment. 
Although care must be taken to select suitable 
cases for home i.v. therapy, with proper back-up very 
few families are in fact unable to benefit from such 
treatment and, although we started this service more 
by serendipity than design, we have had no cause to 
regret its introduction. 
T. K. NINAN AND G. RUSSELL 
Department of Medical Paediatrics 
Royal Aberdeen Children’s Hospital 
Cornhill Road 
Aberdeen AB9 2ZG, U.K. 
3 August 1993 
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Dear Editor 
Mouth blistering and ulceration associated with 
inhaled steroids 
Known steroid inhaler related oral manifestations 
include irritation, dryness, candidiasis, and angina 
bullosa haemorrhagica (1,2). The New Zealand 
Centre for Adverse Reaction Monitoring have 
received four reports of stomatitis associated with 
budesonide and beclomethasone inhalation. 
CASE 1 
A g-year-old boy developed vesicles on the under- 
side of the tongue and inside the lips and gums 1 day 
after commencing budesonide aerosol inhaler 400 pug 
twice daily and terbutaline inhaler, 0.25 mg as necess- 
ary, for nocturnal cough. The inhalers were discon- 
tinued. The vesicles sloughed, the ulcers became 
secondarily infected and resembled herpes stomatitis. 
However, fluorescence and viral cultures were nega- 
tive for herpes simplex, vericella and coxsackie 
viruses. 
CASE2 
A 69-year-old female developed blistering and 
ulceration of the mouth and tongue 10 days after 
commencing budesonide, 400 ,ug dry powder 
(‘Turbuhaler’) twice daily by inhalation for wheeze. 
Resolution followed drug withdrawal. 
CASE 3 
A 61-year-old male developed blistering and ulcer- 
ation of the mouth 2 weeks after starting beclometha- 
sone aerosol inhaler, 5OOpg b.d. for asthma. The 
condition resolved on discontinuing the steroid but 
recurred within a few days on each of two subsequent 
reexposures. 
CASE 4 
A 67-year-old woman developed stomatitis and 
swollen lips after using budesonide aerosol inhaler 
400,~~g for asthma. Rechallenge a month later was 
associated with the same reaction, although the 
patient tolerated inhaled beclomethasone without 
ill-effect. 
The temporal relationship, similar pattern of reac- 
tion, improvement on dechallenge, recurrence on 
rechallenge in the two cases, and the fact that three of 
the four patients were on inhaled steroids alone, 
suggest a causal relationship. The World Health 
Organisation Collaborating Centre for International 
Drug Monitoring have received six other notifi- 
cations of stomatitis, including ulcerative stomatitis, 
associated with inhaled budesonide, 33 with inhaler 
beclomethasone, and four with inhaled flunisolide. 
The entity appears to be distinct from other inhaled 
related oral manifestations including angina bullosa 
haemorrhagica, which is characterized by blood 
blisters, typically on the soft palate, after long term 
(more than 5 years) steroid inhaler use where there is 
demonstrable mucosal atrophy (1,2). 
The mechanism of the steroid-related stomatitis 
described here is unknown. Up to 80% of inhaled 
preparations impact into the oral cavity (3) and the 
reaction may be the consequence of a direct irritant 
effect. Buccal ulceration has been rarely described 
with ipratropium bromide (4) and pharnygeal blis- 
tering with combined ipratropium and terbutaline 
(5). Stomatitis has not been described as one of the 
adverse effects of nondrug components of inhalers, 
such as propellants, preservatives and surfactants, 
or of physical factors such as pH and osmolality 
(6). Furthermore, stomatitis was associated with a 
number of different brands in the WHO reports and 
with the aerosol inhaler and dry powder device 
which would tend to limit the possibility of a 
common causal excipient. Although viral studies 
were negative in the one case where they were 
performed it is possible the reaction simply repre- 
sents activation of latent or subclinical viral infec- 
tion in susceptible individuals due to decreased local 
resistance. 
The stomatitis is troublesome but self-limited, and 
regular prescribers of inhaled steroids may have 
encountered the association. Simple measures such as 
spacer devices which reduce the topical dose, and 
mouth rinsing may obviate the need for withdrawal 
of the steroid inhaler. 
P. PILLANS 
Centrefor Adverse Reaction Monitoring and National 
Toxicology Group 
University of Otago Medical School 
P.O. Box 913 
Dunedin 
New Zealand 
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